These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2302703)

  • 1. Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.
    Colombatti M; Dell'Arciprete L; Chignola R; Tridente G
    Cancer Res; 1990 Mar; 50(5):1385-91. PubMed ID: 2302703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
    Candiani C; Franceschi A; Chignola R; Pasti M; Anselmi C; Benoni G; Tridente G; Colombatti M
    Cancer Res; 1992 Feb; 52(3):623-30. PubMed ID: 1732050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive effects of anti-transferrin receptor immunotoxin in a multicellular tumor spheroid model.
    Chignola R; Foroni R; Candiani C; Franceschi A; Pasti M; Stevanoni G; Anselmi C; Tridente G; Colombatti M
    Int J Cancer; 1994 Apr; 57(2):268-74. PubMed ID: 8157364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
    Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
    Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
    Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL
    J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediation of reduction of spontaneous and experimental pulmonary metastases by ricin A-chain immunotoxin 45-2D9-RTA with potentiation by systemic monensin in mice.
    Roth JA; Ames RS; Fry K; Lee HM; Scannon PJ
    Cancer Res; 1988 Jun; 48(12):3496-501. PubMed ID: 3259469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
    Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
    Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the specific cytotoxicity of a breast cancer-associated antigen immunotoxin by the carboxylic ionophore monensin.
    Griffin TW; Pagnini PG; Houston LL
    J Biol Response Mod; 1987 Oct; 6(5):537-45. PubMed ID: 3500277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
    Ramakrishnan S; Bjorn MJ; Houston LL
    Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
    Kornfeld SB; Leonard JE; Mullen MD; Taetle R
    Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of human glioma cells to cytotoxic heteroconjugates.
    Colombatti M; Bisconti M; Dell'Arciprete L; Gerosa MA; Tridente G
    Int J Cancer; 1988 Sep; 42(3):441-8. PubMed ID: 3138194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro.
    Recht LD; Griffin TW; Raso V; Salimi AR
    Cancer Res; 1990 Oct; 50(20):6696-700. PubMed ID: 2208135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin.
    Krönke M; Schlick E; Waldmann TA; Vitetta ES; Greene WC
    Cancer Res; 1986 Jul; 46(7):3295-8. PubMed ID: 3011246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the cytotoxic effect of anti-carcinoembryonic antigen immunotoxins by adenovirus and carboxylic ionophores.
    Griffin TW; Childs LR; FitzGerald DJ; Levin LV
    J Natl Cancer Inst; 1987 Oct; 79(4):679-85. PubMed ID: 3498854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
    Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
    J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics.
    van Oosterhout YV; Preijers FW; Wessels HM; de Witte T
    Cancer Res; 1992 Nov; 52(21):5921-5. PubMed ID: 1394218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.